Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients - Concepedia

Concepedia

Publication | Closed Access

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

113

Citations

9

References

2007

Year

Richard Haubrich, Dan Berger, Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag,

Abstract

TMC114/r treatment resulted in greater virological and immunological responses in ART-experienced patients compared with CPI at 24 weeks.

References

	Year	Citations
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE> Joel E. Gallant JAMA	2004	1.3K
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America Jacob Lalezari, Keith Henry, Mary O’Hearn, New England Journal of Medicine	2003	909
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates Sandra De Meyer, Hilde Azijn, Dominique Surleraux, Antimicrobial Agents and Chemotherapy Broad RangeProtease InhibitorAntiviral ActivityMedicineHiv-1 Lai	2005	354
The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila, Antiviral Therapy PharmacotherapyAntiviral DrugDrug ResistanceProspective StudiesHuman Retrovirus	2000	330
Drug Resistance Mutations in HIV-1. PubMed Hiv-1 ResistanceMolecular BiologyAntiviral DrugInternational Aids Society-usaDrug Resistance	2003	282
2025 update of the drug resistance mutations in HIV-1. Annemarie M. J. Wensing, Vincent Cálvez, Francesca Ceccherini‐Silberstein, PubMed Regimen SimplificationImmunologyQuantitative PharmacologyPharmacotherapyAntiviral Drug	2005	217
Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients Constance A. Benson, Steven G. Deeks, Scott C. Brun, The Journal of Infectious Diseases	2002	153
Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group Amanda Mocroft, Bruno Ledergerber, Jean Paul Viard, The Journal of Infectious Diseases	2004	87
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study Caroline Sabin, Teresa Hill, Fiona Lampe, BMJ	2005	79

Page 1